Papers for
pharmaceutical developers
Papers whose findings have a practical use for this group, as judged from the abstract. Open a paper to read what it means in practice.
Graph transformer model improves molecular chirality identification
$\text{GSF-}χ$: Global Stereochemical Fields for Chiral Graph Transformers
Abstract: Enantiomers share atoms, bonds, and pairwise distances yet can behave differently in chiral environments, so molecular encoders must respect atom relabelings and proper rotations without becoming blind to reflection. We introduce GSF-$χ$, a graph transformer in which stereogenic units modulate all pairwise interactions rather than single out one atom as special. Each central or axial stereogenic unit creates a reflection-even phase field over all atoms, a handedness pseudoscalar $χ$ sets the direction of a relative rotation on latent query--key blocks, giving a \textbf{Chiral-RoPE} that reflection inverts rather than leaves fixed. A $C_2$ projection separates mirror-even ECD peak counts and positions from mirror-odd peak signs. We prove the operator's even--odd decomposition and its annotation-inversion, permutation, and unit-order identities under explicit canonical-role conditions; property tests and a coordinate-reflection audit verify the laws end to end. GSF-$χ$ leads every central-ECD output and improves axial Rotation and Symbol by $12.6\%$ and $7.9\%$ over the strongest baseline. Equal-budget controls attribute the Rotation advantage to global signed support rather than parameter or edge count; the $C_2$ projection yields exact enantiomer-pair consistency at a small raw-accuracy cost under complete supervision and becomes predictive when mirror supervision is scarce.
Transformer model predicts cell responses to psilocybin drug effects
A Transformer-Based Delta Expression Encoder for Psilocybin Transcriptional Response: Architecture, Representations, and Biological Validation
Abstract: Understanding why individuals respond differently to psilocybin requires modeling the drug's transcriptional perturbation signature at the cell-type level. I present a Transformer-based delta expression encoder that learns to classify differential gene expression status - upregulated, downregulated, or neutral - from single-nucleus RNA-sequencing data, without supervision from pathway annotations or prior biological knowledge. The model is trained on pseudobulk profiles from 623 examples spanning 18 cell types, 2 drug conditions, and 6 timepoints derived from the Liao et al. 2025 dataset, and achieves 69.4% weighted classification accuracy. Three principal findings are reported, alongside one direct test of a published hypothesis that returned a result inconsistent with that hypothesis. First, per-cell-type classification accuracy ranges from 28.3% (L2/3 IT, a primary HTR2A-expressing psilocybin target) to 99.6% (endothelial cells), consistent with known psilocybin response biology. Second, psilocybin-induced transcriptional downregulation is significantly more stereotyped across individuals than upregulation (Mann-Whitney U=18615.0, p<0.0001), a novel finding with a cortical depth gradient across excitatory subtypes. Third, attention-guided gene co-regulation analysis recovers drug-specific modules without pathway supervision. Separately, a direct test of whether baseline HTR2A expression predicts drug-response separability across cell types found a significant negative correlation (Spearman r = -0.7088, p = 0.0021), the opposite of what a simple HTR2A-gating account would predict.